CONMED Reports Mixed Q4/FY25 Results, Issues Lower FY26 Adjusted EPS Guidance
CNMD is trading near its 52-week low of $38.32 (3.5% above the low).
Summary
CONMED reported mixed Q4 and full-year 2025 results with strong revenue growth but a significant GAAP EPS decline, and issued 2026 adjusted EPS guidance below 2025 levels.
Key Events · Earnings and Guidance · CNMD
-
Q4 and Full-Year 2025 Financial Results Announced
CONMED reported Q4 2025 sales of $373.2 million, up 7.9% year-over-year, and full-year 2025 sales of $1,374.7 million, up 5.2%. Adjusted diluted EPS for Q4 was $1.43 (up from $1.34) and for full-year 2025 was $4.59 (up from $4.17).
-
Significant GAAP EPS Decline
Despite adjusted EPS growth, diluted GAAP net earnings per share fell sharply to $0.54 in Q4 2025 (from $1.08 in Q4 2024) and to $1.51 for full-year 2025 (from $4.25 in 2024), indicating substantial non-GAAP adjustments.
-
Lower 2026 Adjusted EPS Guidance Issued
The company provided full-year 2026 adjusted diluted net earnings per share guidance in the range of $4.30 to $4.45, which is lower than the $4.59 reported for full-year 2025.
-
2026 Revenue Guidance Confirmed
Full-year 2026 reported revenue is expected to be between $1.345 billion and $1.375 billion, representing organic constant currency growth of approximately 4.5% to 6% over 2025 revenue, excluding gastroenterology products.
Analysis · CNMD · Industrial Applications And Services
CONMED Corporation's latest earnings report presents a mixed financial picture. While the company achieved solid revenue growth in Q4 and full-year 2025, and adjusted diluted EPS increased for 2025, the significant decline in GAAP diluted EPS for both periods is a notable concern. More critically, the full-year 2026 adjusted diluted EPS guidance is set below the 2025 adjusted EPS, signaling a potential deceleration in profitability. This guidance, coupled with the stock currently trading near its 52-week low, could pressure investor sentiment. Investors should monitor the impact of the strategic shift regarding gastroenterology products on future revenue and the company's ability to improve GAAP profitability.
At the time of this filing, CNMD was trading at $39.68 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $38.32 to $74.70. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.